|
Hear what GI professionals are saying about this product
|
|
PLENVU® from an expert point of VU
{{customText[Hello|Hi|Dear]}} {{customText[Dr|Mr|Mrs|Ms]}}. {{accLname}},
PLENVU® offers the
convenience of a proven cleanse with low‑volume flexible dosing, allowing patients to prep using either a 2‑day split or same‑day morning‑of-colonoscopy regimen.1,2
With that in mind, we would like to share the following videos, which highlight the experiences of fellow GI professionals who have prescribed PLENVU® for their patients.
|
|
Katie Farah, MD
Dr. Farah discusses why she adopted PLENVU® into her practice,
what patients can expect when taking it, and more.
|
|
INDICATION
PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.
IMPORTANT SAFETY INFORMATION
- PLENVU® is contraindicated in patients with gastrointestinal (GI) obstruction, bowel
perforation, gastric retention, ileus, toxic megacolon, and hypersensitivity to any of
its ingredients.
Please see additional Important Safety Information throughout and click here for full Prescribing Information.
|
|
David Poppers, MD, PhD
Dr. Poppers discusses results he has seen when prescribing PLENVU®, patient satisfaction, support materials, and more.
|
|
|
We hope you find these videos helpful.
To watch the full versions, click the link below.
|
|
|
|
|
|
Want to streamline the bowel prep process?
Access comprehensive resources at the link below.
|
|
|
|
IMPORTANT SAFETY INFORMATION (continued)
- Advise patients to hydrate adequately before, during, and after the use of PLENVU®.
It is encouraged that patients drink additional clear liquids to help avoid cases of
fluid and electrolyte abnormalities. Fluid and electrolyte disturbances can lead to
serious adverse events including cardiac arrhythmias, seizures, and renal impairment.
- There have been rare reports of serious arrhythmias associated with the use of ionic
osmotic laxative products for bowel preparation. These occur predominantly in
patients with underlying cardiac risk factors and electrolyte disturbances. Consider
obtaining ECGs in patients at an increased risk of serious cardiac arrhythmias.
- Use PLENVU® with caution in patients with a history of seizures and those at an
increased risk of seizures, including patients taking medications that lower the seizure threshold, patients withdrawing from alcohol or benzodiazepines, or patients
with hyponatremia.
- Use PLENVU® with caution in patients with renal impairment or those taking
concomitant medications that affect renal function. Advise these patients to
adequately hydrate before, during, and after the use of PLENVU® and consider
performing laboratory tests in these patients.
- Do not administer PLENVU® to patients with GI obstruction or perforation. If GI obstruction or perforation is suspected, perform appropriate diagnostic studies prior to administering PLENVU®.
- Use caution in patients with severe ulcerative colitis.
- Patients with impaired gag reflex or those prone to regurgitation or aspiration should be observed during the administration of PLENVU®. Use with caution in these patients. Do not combine PLENVU® with starch-based thickeners.
- Use PLENVU® with caution in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
- Phenylalanine can be harmful to patients with phenylketonuria (PKU). PLENVU® contains phenylalanine, a component of aspartame. Each PLENVU® treatment contains 491 mg of phenylalanine.
- PLENVU® contains polyethylene glycol and may cause serious hypersensitivity reactions including anaphylaxis, angioedema, rash, urticaria, and pruritus. Inform patients of the signs and symptoms of anaphylaxis and instruct them to seek immediate medical care should signs and symptoms occur.
- In clinical trials, the most common adverse reactions (>2% of patients taking PLENVU®) were nausea, vomiting, dehydration, and abdominal pain/discomfort. Adverse reactions were similar between the two dosing regimens.
|
|
To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please click here for full Prescribing Information.
|
|
Sincerely,
{{userName}}
{{User.Phone}}
{{userEmailAddress}}
|
|
References:
1. Plenvu. Prescribing information. Salix Pharmaceuticals, a division of Bausch Health US, LLC; 2023. 2. DeMicco MP et al. Gastrointest Endosc.
2018;87(3):677-687.e3
|
|
Be advised this communication comes to you from an unmonitored mailbox: replies to this mailbox will not be received or answered. If you need further assistance, please reach out to your local Salix Representative.
This email was sent to you because you are valued customer. If you no longer wish to
receive these emails, you may unsubscribe here at any time.
|
|
|
|
Salix Pharmaceuticals
400 Somerset Corporate Blvd │ Bridgewater, NJ 08807
This email was sent to {{accEmail}} because you opted in/requested to receive PLENVU® messages from Salix Pharmaceuticals.
If you no longer wish to receive emails from Salix Pharmaceuticals, you can update your email preferences below.
Please do not reply to this email. If you have questions related to our products, contact our Customer Care at 1-800-321-4576.
|
|
UNSUBSCRIBE OR UPDATE EMAIL PREFERENCES | PRIVACY POLICY | LEGAL NOTICE
|
|
